Compare Novo Nordisk A/S (NVO) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Okta, Inc. — how do they compare? Novo Nordisk A/S trades at $38.62 (market cap $165.31B), while Okta, Inc. trades at $232.4 (market cap $38.50B). The key difference: Novo Nordisk A/S is far larger — about 4.3× Okta, Inc.'s market cap, and Novo Nordisk A/S pays a 4.71% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Okta, Inc. for 44 Days on average.
| NVO | OKTA | |
|---|---|---|
Market Cap | $165.31B | $38.50B |
Volume | 11,432,838 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $63.98 | $220.21 |
52-Week Low | $35.29 | $62.93 |
Typical Hold Time | 116 Days | 44 Days |
Enterprise Value | $179.56B | $36.25B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
OKTA's stock trades at $232.13, up 6.48% in the last 24 hours, reflecting strong momentum. The technical outlook is bullish, with the price near resistance at $232. Recent earnings beats and a strategic focus on AI agent security, highlighted at the Oktane 2026 conference, support positive sentiment. However, valuation ratios like a P/E of 132.66 and P/S of 12.74 indicate a premium, while the company has only recently achieved profitability with a net income margin of 1.07% in 2025.
The outlook is cautiously optimistic, driven by revenue growth and AI positioning, but high valuation and competitive pressures pose risks. Analyst consensus is strongly bullish with a 73.58% buy rating, though the current price exceeds the consensus target of $201.30, suggesting near-term consolidation may occur. Investors should weigh growth potential against premium multiples and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
